U.K. Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (Contract Outsourcing, In-house), By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-use, And Segment Forecasts, 2021 - 2028

Table of Contents

Chapter 1 Research Methodology & Scope
                   1.1 Market Segmentation & Scope
                       1.1.1 Service Provider
                       1.1.2 Type
                       1.1.3 Product Life Cycle
                       1.1.4 Process Flow
                       1.1.5 Therapeutic area
                       1.1.6 End use
                       1.1.7 Country Scope
                       1.1.8 Estimates and Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased database:
                       1.3.2 GVR’s Internal Database
                       1.3.3 Secondary sources
                       1.3.4 Primary Research:
                       1.3.5 Details of Primary Research
                            1.3.5.1 Data for primary interviews
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                   1.7 List of Secondary Sources
                   1.8 List of Abbreviations
                   1.9 Market Definitions
                   1.10 Report Objectives
                       1.10.1 Objective 1:
                       1.10.2 Objective 2:
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 U.K. Pharmacovigilance Market Outlook, 2016 - 2028 (USD Million)
                   2.3 Segment Outlook
                   2.4 Competitive Outlook
Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent market analysis
                       3.1.2 Ancillary market Analysis
                   3.2 Penetration & Growth Prospect Mapping
                   3.3 Pharmacovigilance Market Dynamics
                       3.3.1 Market driver analysis
                       3.3.2 Market restraint analysis
                       3.3.3 Industry Challenges
                   3.4 U.K. Pharmacovigilance Market Analysis Tools: Porters
                   3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
                   3.6 Value Chain Analysis
                       3.6.1 Pre-clinical
                       3.6.2 Clinical
                       3.6.3 PMA
                   3.7 Mapping of Life Cycle Against Service Offering and Their Demand
                   3.8 Regulatory Framework
                   3.9 Pharmacovigilance: Organization Structure Introduction
                   3.10 Pricing Models
                       3.10.1 Drug safety Budget Allocation by Activities
                       3.10.2 By Development phase
                       3.10.3 By Therapeutic area
                       3.10.4 Pricing Level
                           3.10.4.1 Case processing
                           3.10.4.2 ADR Reporting
                           3.10.4.3 Medical writing
                           3.10.4.4 Drug safety management
                   3.11 Technology Timeline Overview
                       3.11.1 Changing Technology & Adoption
                           3.11.1.1 Social Media
                           3.11.1.2 Literature screening
                           3.11.1.3 Automation and AI
                           3.11.1.4 Big data analytics in PV
Chapter 4 COVID-19 Impact Analysis
                   4.1 COVID-19 Outbreak
                       4.1.1 U.K.: COVID-19 Disease Prevalence
                   4.2 Current and Future Impact Analysis
                   4.3 Recent Developments & Strategic Outcomes
                       4.3.1 Regulatory requirements/changes due to Covid-19
                       4.3.2 Strategies implemented by companies
                           4.3.2.1 IQVIA
                           4.3.2.2 PARAXEL International Corporation
                           4.3.2.3 Bioclinica
                           4.3.2.4 Pharmaceutical Product Development (PPD)
                           4.3.2.5 IBM Corporation
                           4.3.2.6 ICON, plc
                           4.3.2.7 ArisGlobal
Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis
                   5.1 Service Provider Market Share Analysis, 2020 & 2028
                   5.2 Service Provider Dashboard
                       5.2.1 In-house
                           5.2.1.1 In-house market estimates and forecasts, 2016 - 2028 (USD Million)
                       5.2.2 Contract Outsourcing
                           5.2.2.1 Contract outsourcing market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis
                   6.1 Type Market Share Analysis, 2020 & 2028
                   6.2 Type Dashboard
                       6.2.1 Spontaneous Reporting
                           6.2.1.1 Spontaneous Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
                       6.2.2 Intensified ADR Reporting
                           6.2.2.1 Intensified ADR Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
                       6.2.3 Targeted Spontaneous Reporting
                           6.2.3.1 Targeted spontaneous reporting market estimates and forecasts, 2016 - 2028 (USD Million)
                       6.2.4 Cohort Event Monitoring (CEM)
                           6.2.4.1 CEM market estimates and forecasts, 2016 - 2028 (USD Million)
                       6.2.5 EHR Mining
                           6.2.5.1 EHR Mining market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis
                   7.1 Product Life Cycle Market Share Analysis, 2020 & 2028
                   7.2 Product Dashboard
                       7.2.1 Pre-clinical
                           7.2.1.1 Pre-clinical market estimates and forecasts, 2016 - 2028 (USD Million)
                       7.2.2 Phase I
                           7.2.2.1 Phase I market estimates and forecasts, 2016 - 2028 (USD Million)
                       7.2.3 Phase II
                           7.2.3.1 Phase II market estimates and forecasts, 2016 - 2028 (USD Million)
                       7.2.4 Phase III
                           7.2.4.1 Phase III market estimates and forecasts, 2016 - 2028 (USD Million)
                       7.2.5 Phase IV
                           7.2.5.1 Phase IV market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
                   8.1 Process Flow Market Share Analysis, 2020 & 2028
                   8.2 Process Flow Dashboard
                       8.2.1 Case data management
                           8.2.1.1 Case data management market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.1.2 Case logging
                           8.2.1.3 Case logging market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.1.4 Case data analysis
                           8.2.1.5 Case data analysis market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.1.6 Medical reviewing and reporting
                           8.2.1.7 Medical reviewing and reporting market estimates and forecasts, 2016 - 2028 (USD Million)
                       8.2.2 Signal detection
                           8.2.2.1 Signal detection market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.2.2 Adverse Event Logging
                           8.2.2.3 Adverse Event Logging market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.2.4 Adverse Event Analysis
                           8.2.2.5 Adverse Event Analysis market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.2.6 Adverse Event Review & Reporting
                           8.2.2.7 Adverse Event Review & Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
                       8.2.3 Risk Management System
                           8.2.3.1 Risk Management System market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.3.2 Risk Evaluation System
                           8.2.3.3 Risk Evaluation System market estimates and forecasts, 2016 - 2028 (USD Million)
                           8.2.3.4 Risk Mitigation System
                           8.2.3.5 Risk Mitigation System market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
                   9.1 Therapeutic Area Market Share Analysis, 2020 & 2028
                   9.2 Therapeutic Area Dashboard
                       9.2.1 Oncology
                           9.2.1.1 Oncology market estimates and forecasts, 2016 - 2028 (USD Million)
                       9.2.2 Neurology
                           9.2.2.1 Neurology market estimates and forecasts, 2016 - 2028 (USD Million)
                       9.2.3 Cardiology
                           9.2.3.1 Cardiology market estimates and forecasts, 2016 - 2028 (USD Million)
                       9.2.4 Respiratory systems
                           9.2.4.1 Respiratory systems market estimates and forecasts, 2016 - 2028 (USD Million)
                       9.2.5 Others
                           9.2.5.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 10 Pharmacovigilance Market: End-use Estimates & Trend Analysis
                   10.1 End-use Market Share Analysis, 2020 & 2028
                   10.2 End-use Dashboard
                       10.2.1 Pharmaceuticals
                           10.2.1.1 Pharmaceuticals market estimates and forecasts, 2016 - 2028 (USD Million)
                       10.2.2 Biotechnology Companies
                           10.2.2.1 Biotechnology companies market estimates and forecasts, 2016 - 2028 (USD Million)
                       10.2.3 Medical Device Manufacturers
                           10.2.3.1 Medical Device Manufacturers market estimates and forecasts, 2016 - 2028 (USD Million)
                       10.2.4 Others
                           10.2.4.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 11 Competitive Outlook
                   11.1 Market Participation Categorization
                   11.2 Public Companies
                       11.2.1 Company market position analysis
                       11.2.2 Consolidation Trends
                   11.3 Private Companies
                       11.3.1 List of key emerging companies
Chapter 12 Company Profiles
                   12.1 Accenture
                       12.1.1 Company overview
                       12.1.2 Service benchmarking
                       12.1.3 Organization structure & Team Composition
                           12.1.3.1 Team composition
                       12.1.4 Financial performance
                       12.1.5 R&D expenditure
                       12.1.6 Strategic initiatives
                       12.1.7 SWOT Analysis
                   12.2 IQVIA
                       12.2.1 Company overview
                       12.2.2 Service benchmarking
                       12.2.3 Organization structure & Team Composition
                           12.2.3.1 Team composition
                       12.2.4 Financial performance
                       12.2.5 Strategic initiatives
                       12.2.6 SWOT Analysis
                   12.33 Cognizant
                       12.3.1 Company overview
                       12.3.2 Service benchmarking
                       12.3.3 Organization structure & Team Composition
                           12.3.3.1 Team composition
                       12.3.4 Financial performance
                       12.3.5 Strategic initiatives
                       12.3.6 SWOT Analysis
                   12.4 IBM Corporation
                       12.4.1 Company overview
                       12.4.2 Service benchmarking
                       12.4.3 Organization structure & Team Composition
                           12.4.3.1 Team composition
                       12.4.4 Financial performance
                       12.4.5 R&D expenditure
                       12.4.6 Strategic initiatives
                       12.4.7 SWOT Analysis
                   12.5 ArisGlobal
                       12.5.1 Company overview
                       12.5.2 Service benchmarking
                       12.5.3 Organization structure & Team Composition
                           12.5.3.1 Team composition
                       12.5.4 Financial performance
                       12.5.5 Strategic initiatives
                       12.5.6 SWOT Analysis
                   12.6 ICON Plc.
                       12.6.1 Company overview
                       12.6.2 Service benchmarking
                       12.6.3 Organization structure & Team Composition
                           12.6.3.1 Team composition
                       12.6.4 Financial performance
                       12.6.5 Strategic initiatives
                       12.6.6 SWOT Analysis
                   12.7 Capgemini
                       12.7.1 Company overview
                       12.7.2 Service benchmarking
                       12.7.3 Organization structure & Team Composition
                           12.7.3.1 Team composition
                       12.7.4 Financial performance
                       12.7.5 Strategic initiatives
                       12.7.6 SWOT Analysis
                   12.8 TAKE Solutions
                       12.8.1 Company overview
                       12.8.2 Service benchmarking
                       12.8.3 Organization structure & Team Composition
                           12.8.3.1 Team composition
                       12.8.4 Financial performance
                       12.8.5 Strategic initiatives
                       12.8.6 SWOT Analysis
                   12.9 PAREXEL International Corporation
                       12.9.1 Company overview
                       12.9.2 Service benchmarking
                       12.9.3 Organization structure & Team Composition
                           12.9.3.1 Team composition
                       12.9.4 Financial performance
                       12.9.5 Strategic initiatives
                       12.9.6 SWOT Analysis
                   12.10 BioClinica, Inc.
                       12.10.1 Company overview
                       12.10.2 Service benchmarking
                       12.10.3 Organization structure & Team Composition
                           12.10.3.1 Team composition
                       12.10.4 Financial performance
                       12.10.5 Strategic initiatives
                       12.10.6 SWOT Analysis
Chapter 13 Winning Strategies
                   13.1 Key Winning/Scoring Criteria’s
                       13.1.1 By categories
                           13.1.1.1 Pharmaceuticals
                           13.1.1.2 Biotech companies
                           13.1.1.3 Medical device companies
                   13.2 Key Vendor Selection Factors
                       13.2.1 By Category
                       13.2.2 BY Company size
                           13.2.2.1 KEY TAKEAWAYS
                   13.3 Switching Cost Analysis
                   13.4 Detailed List of Companies

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 3 Types of ADRs
Table 4 Adverse Drug Events (ADEs) in hospitals
Table 5 Total literature searches (2013 - 2019)
Table 6 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
Table 7 Case management costing by year
Table 8 Price by case processing volume
Table 9 Outsourcing trend observed in pharmaceutical companies
Table 10 List of Major Deals & Acquisitions
Table 11 Detailed list of companies in clinical trials in pharmacovigilance

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
Fig. 10 U.K. Pharmacovigilance Market Estimates and Revenue Forecast, 2016 - 2028 (USD Million)
Fig. 11 U.K. Pharmacovigilance market snapshot, 2020 (USD Million)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Pharmacovigilance market dynamics
Fig. 14 Pharmacovigilance market driver impact
Fig. 15 Pharmacovigilance market restraint impact
Fig. 16 Porter’s five force model
Fig. 17 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 18 Trending topics on social media (2017)
Fig. 19 ADR detection and from social media data
Fig. 20 Common literature automation tool flow
Fig. 21 Automation processes in PV
Fig. 22 Deterrents to Leveraging the Cloud (Oracle Survey)
Fig. 23 The three-step process to compute signal statistics from search log using big data
Fig. 24 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
Fig. 25 Pharmacovigilance & Patient Safety Services - Product Life Cycle
Fig. 26 PV department
Fig. 27 PV organization structure
Fig. 28 Estimated budget allocation of drug safety activities at global and country-level
Fig. 29 Comparison between estimated global and country-level drug safety budget allocation
Fig. 30 Average % of drug safety budget contributed by function at a global level
Fig. 31 Clinical trial cost by phase (%)
Fig. 32 The average monthly cost of illness due to ADRs
Fig. 33 Covid-19 disease prevalence analysis
Fig. 34 Pharmacovigilance market: Product life cycle movement analysis
Fig. 35 Pharmacovigilance market product life cycle dashboard
Fig. 36 Preclinical market, 2016 - 2028 (USD Million)
Fig. 37 Phase I market, 2016 - 2028 (USD Million)
Fig. 38 Phase II market, 2016 - 2028 (USD Million)
Fig. 39 Phase III market, 2016 - 2028 (USD Million)
Fig. 40 Phase IV market, 2016 - 2028 (USD Million)
Fig. 41 U.K. Pharmacovigilance market: Service provider movement analysis
Fig. 42 Pharmacovigilance Service provider dashboard
Fig. 43 In-house market, 2016 - 2028 (USD Million)
Fig. 44 Contract outsourcing market, 2016 - 2028 (USD Million)
Fig. 45 U.K. Pharmacovigilance market: Type movement analysis
Fig. 46 Pharmacovigilance type dashboard
Fig. 47 Spontaneous reporting market, 2016 - 2028 (USD Million)
Fig. 48 Intensified ADR reporting market, 2016 - 2028 (USD Million)
Fig. 49 Targeted spontaneous reporting market, 2016 - 2028 (USD Million)
Fig. 50 CEM market, 2016 - 2028 (USD Million)
Fig. 51 EHR mining market, 2016 - 2028 (USD Million)
Fig. 52 U.K. Pharmacovigilance market: Process flow movement analysis
Fig. 53 U.K. Pharmacovigilance market process flow dashboard
Fig. 54 Case data management market, 2016 - 2028 (USD Million)
Fig. 55 Case logging market, 2016 - 2028 (USD Million)
Fig. 56 Case data analysis market, 2016 - 2028 (USD Million)
Fig. 57 Medical reviewing and reporting market, 2016 - 2028 (USD Million)
Fig. 58 Signal detection market, 2016- 2028 (USD Million)
Fig. 59 Adverse event logging market, 2016 - 2028 (USD Million)
Fig. 60 Adverse event analysis market, 2016 - 2028 (USD Million)
Fig. 61 adverse event review & reporting market, 2016 - 2028 (USD Million)
Fig. 62 Risk management system market, 2016 - 2028 (USD Million)
Fig. 63 Risk Evaluation System market, 2016 - 2028 (USD Million)
Fig. 64 Risk mitigation system market, 2016 - 2028 (USD Million)
Fig. 65 U.K. Pharmacovigilance market: Therapeutic area movement analysis
Fig. 66 Pharmacovigilance market therapeutic area dashboard
Fig. 67 Oncology market, 2016 - 2028 (USD Million)
Fig. 68 neurology market, 2016 - 2028 (USD Million)
Fig. 69 cardiology market, 2016 - 2028 (USD Million)
Fig. 70 respiratory systems market, 2016 - 2028 (USD Million)
Fig. 71 others market, 2016 - 2028 (USD Million)
Fig. 72 U.K. Pharmacovigilance market: End-use movement analysis
Fig. 73 Pharmacovigilance market end-use dashboard
Fig. 74 Pharmaceuticals market, 2016 - 2028 (USD Million)
Fig. 75 Biotechnology companies’ market, 2016 - 2028 (USD Million)
Fig. 76 Medical device manufacturers market, 2016 - 2028 (USD Million)
Fig. 77 Others market, 2016 - 2028 (USD Million)
Fig. 78 Market participant categorization
Fig. 79 Company market position analysis
Fig. 80 Organization Structure - Accenture
Fig. 81 SWOT - Accenture
Fig. 82 Organization Structure - IQVIA
Fig. 83 SWOT - IQVIA
Fig. 84 Organization Structure - Cognizant
Fig. 85 SWOT - Cognizant
Fig. 86 Organization Structure - IBM
Fig. 87 SWOT - IBM
Fig. 88 Organization Structure - ArisGlobal
Fig. 89 SWOT - ArisGlobal
Fig. 90 Organization Structure - ICON Plc
Fig. 91 SWOT - ICON Plc
Fig. 92 Organization Structure - Capgemini
Fig. 93 SWOT - Capgemini
Fig. 94 Organization Structure - Take Solutions
Fig. 95 SWOT - Take Solutions
Fig. 96 Organization Structure - Paraxel Corporation
Fig. 97 SWOT - PARAXEL
Fig. 98 Organization Structure - BioClinica, Inc.
Fig. 99 SWOT - BioClinica, Inc.
Fig. 100 Commonly outsourced PV activities
Fig. 101 Vendor selection criteria